Elevance Health stock trades steadily as earnings and Medicaid growth shape investor focus

Elevance Health Inc. (ISIN US2855211023) reported continued earnings growth and expanding government program membership in its most recent quarterly update, giving Elevance Health stock a fundamental backdrop that investors can quantify even as the broader managed care sector digests reimbursement and policy shifts.

Net income rises to $2.5 billion

According to Elevance Health's latest earnings release for the quarter ended 31 March 2026, the health benefits company generated net income of approximately $2.5 billion, up from about $2.1 billion in the same quarter a year earlier, an increase of roughly 19% that highlights its ability to grow profit despite cost pressures and regulatory complexity.

The company reported operating revenue of around $42.0 billion in this quarter, compared with roughly $39.0 billion in the prior year period, implying revenue growth of about 7.7% year over year as membership expanded across commercial and government segments and premium yields reflected contract updates and benefit adjustments.

Management indicated in that quarterly update that adjusted earnings per share reached approximately $10.10 for the quarter, compared with about $8.75 a year earlier, representing growth of roughly 15.4%, a pace that outstripped the company's reported revenue growth and underscored operating leverage and disciplined cost management.

Operating margin holds near 6.0 percent

Elevance Health also reported an operating margin of about 6.0% for the quarter ended 31 March 2026, broadly in line with the approximately 5.8% margin recorded in the prior year quarter, suggesting that higher medical costs and administrative expenses were being balanced by premium rates, product mix, and cost-control initiatives rather than eroding profitability.

The company detailed in its segment disclosure that its Commercial & Specialty Business contributed operating revenue of approximately $20.5 billion in the most recent quarter, up from about $19.3 billion a year earlier, an increase of roughly 6.2%, while its Government Business revenue rose to about $21.5 billion from roughly $19.7 billion, a growth rate of about 9.1% that reflected strength in Medicaid and Medicare membership.

On the earnings call, Elevance Health's leadership emphasized that medical cost trends, including pharmacy benefits and specialty drugs, were tracking within expectations for the quarter, and that the company remained focused on clinical quality and care management programs designed to support members with chronic conditions and drive better outcomes.

Government programs add over 1 million members

Elevance Health's Government Business segment, which includes Medicaid and Medicare Advantage plans as well as associated managed care services, reported membership of roughly 15.2 million lives at the end of the quarter, up from about 14.1 million a year earlier, an increase of around 1.1 million members that helped drive the near 9% government revenue growth noted in the earnings release.

Within Medicaid specifically, membership rose to approximately 11.0 million, compared with about 10.1 million a year earlier, as Elevance Health expanded existing contracts, won new awards in certain states, and navigated redeterminations that followed the end of pandemic-era continuous coverage policies, demonstrating its continued role in state public health programs.

Medicare Advantage membership stood near 4.2 million at the quarter's end, up from roughly 4.0 million a year earlier, a gain of about 5% that reflected the company's focus on benefit design, star ratings, and local market relationships with providers, even as competitive dynamics remained intense and federal payment benchmarks continued to shift.

Carelon drives diversified revenue base

Elevance Health's Carelon health services segment, which houses pharmacy benefit management, behavioral health, and other care-management and analytics solutions, recorded revenue of approximately $12.0 billion in the most recent quarter, up from around $10.5 billion a year earlier, translating to growth of roughly 14.3% and reinforcing the company's strategy of building a diversified set of health service capabilities beyond traditional insurance.

The earnings disclosure indicated that Carelon contributed more than one quarter of Elevance Health's consolidated operating revenue in this period, compared with just under one quarter a year earlier, demonstrating that higher growth in services is gradually increasing its share of the overall revenue mix and providing alternative earnings streams that are less directly tied to premium rates.

Management pointed to continued investment in data analytics, digital tools, and value-based care arrangements within Carelon, with a focus on enabling providers and health systems to manage total cost of care for complex populations and to support employer clients looking for integrated benefit solutions spanning medical, pharmacy, and behavioral health.

Anthem branded plans remain core product

Elevance Health continues to market individual and group health plans under the Anthem brand across multiple US states, with these plans forming a central part of its Commercial & Specialty Business and Government Business portfolios and representing a key interface between the company and its employer, individual, and public-sector customers.

In the most recent quarter, Anthem branded commercial medical membership remained broadly stable at around 32 million lives, with modest growth in certain large-group and small-group segments offset by competitive pressure and churn in individual markets, while product offerings emphasized access to broad provider networks, telehealth services, and wellness programs aligned with employers' benefits strategies.

The company has also used the Anthem brand to support employer clients in adopting value-based benefit designs, integrating medical and pharmacy coverage, and offering mental health support and digital engagement tools, positioning the product line as a platform for innovation in care management while maintaining the scale needed to negotiate effectively with health systems and pharmaceutical manufacturers.

Shares trade in upper half of 52-week range

Elevance Health stock is listed on the New York Stock Exchange under the symbol ELV and recently traded near $530 per share, placing it in the upper half of its 52-week trading range between approximately $420 and $550 per share, a range that reflects both sector-wide concerns over medical cost trends and investor appreciation of the company's steady earnings growth.

At this share price, Elevance Health's equity value corresponds to a market capitalization of roughly $61 billion, using common share counts disclosed in recent filings, situating the company among the larger constituents of major US equity indices and underlining its importance in the managed care and health services ecosystem.

While Elevance Health does not set its stock price, the combination of earnings growth, membership expansion, and investment in health services such as Carelon provides a framework for investors to assess the company's valuation against peers in the managed care space and against broader US market benchmarks.